Patents Assigned to Bolder Biotechnology, Inc.
-
Patent number: 8148500Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: GrantFiled: September 21, 2010Date of Patent: April 3, 2012Assignee: Bolder BioTechnology, Inc.Inventors: George N. Cox, III, Daniel H. Doherty
-
Patent number: 8133480Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.Type: GrantFiled: February 24, 2009Date of Patent: March 13, 2012Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox, III
-
Patent number: 7994124Abstract: The present invention relates to therapeutic methods for a protecting an animal from a disease or condition that can be treated by granulocyte colony-stimulating factor (G-CSF) wherein a composition comprising a cysteine variant of G-CSF is provided. Also disclosed herein are preferred cysteine variants of G-CSF for use in the composition.Type: GrantFiled: November 2, 2009Date of Patent: August 9, 2011Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox
-
Publication number: 20110189124Abstract: The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins.Type: ApplicationFiled: September 29, 2010Publication date: August 4, 2011Applicant: BOLDER BIOTECHNOLOGY INC.Inventors: Mary S. Rosendahl, George N. Cox, Daniel H. Doherty
-
Publication number: 20110172151Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: ApplicationFiled: September 21, 2010Publication date: July 14, 2011Applicant: BOLDER BIOTECHNOLOGY, INC.Inventors: George N. Cox, III, Daniel H. Doherty
-
Patent number: 7959909Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: GrantFiled: October 30, 2007Date of Patent: June 14, 2011Assignee: Bolder BioTechnology, Inc.Inventor: George N. Cox, III
-
Patent number: 7947655Abstract: The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.Type: GrantFiled: October 22, 2009Date of Patent: May 24, 2011Assignee: Bolder Biotechnology, Inc.Inventors: George N. Cox, III, Daniel H. Doherty, Mary S. Rosendahl
-
Publication number: 20100285014Abstract: The present invention relates to novel methods for making fusion proteins comprising a cytokine or growth factor fused to an immunoglobulin domain. The growth factor/cytokine can be fused directly to an immunoglobulin domain or through a peptide linker. The purified growth factor/cytokine-IgG fusion proteins produced by the novel methods are biologically active and can be used to treat diseases for which the non-fused growth factor/cytokine are useful.Type: ApplicationFiled: May 10, 2010Publication date: November 11, 2010Applicant: BOLDER BIOTECHNOLOGY, INC.Inventors: George N. Cox, III, Daniel H. Doherty
-
Patent number: 7824669Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: GrantFiled: July 14, 2009Date of Patent: November 2, 2010Assignee: Bolder Biotechnology, Inc.Inventors: George N. Cox, III, Daniel H. Doherty
-
Publication number: 20100266529Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: ApplicationFiled: November 2, 2009Publication date: October 21, 2010Applicant: BOLDER BIOTECHNOLOGY, INC.Inventor: George N. Cox, III
-
Patent number: 7795396Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: GrantFiled: March 2, 2005Date of Patent: September 14, 2010Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox, III
-
Patent number: 7754855Abstract: The present invention relates to novel methods for making fusion proteins comprising a cytokine or growth factor fused to an immunoglobulin domain. The growth factor/cytokine can be fused directly to an immunoglobulin domain or through a peptide linker. The purified growth factor/cytokine-IgG fusion proteins produced by the novel methods are biologically active and can be used to treat diseases for which the non-fused growth factor/cytokine are useful.Type: GrantFiled: July 13, 2000Date of Patent: July 13, 2010Assignee: Bolder Biotechnology, Inc.Inventors: George N. Cox, III, Daniel H. Doherty
-
Patent number: 7732572Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: GrantFiled: June 10, 2004Date of Patent: June 8, 2010Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox, III
-
Publication number: 20100121032Abstract: Disclosed is a method for refolding a protein or peptide that does not contain essential disulfides and that contains at least one free cysteine residue. Also disclosed are polymer IFN-? conjugates that have been created by the chemical coupling of polymers such as polyethylene glycol moieties to IFN-?, particularly via a free cysteine in the protein. Also disclosed are analogs of bioactive peptides that may be used to create longer acting versions of the peptides, including analogs of glucagon, glucagon-like peptide-1 (GLP-1), GLP-2, Gastric inhibitory peptide (GIP), PYY, exendin, ghrelin, gastrin, amylin, and oxyntomodulin.Type: ApplicationFiled: December 14, 2007Publication date: May 13, 2010Applicant: BOLDER BIOTECHNOLOGY, INC.Inventors: George N. Cox, Mary S. Rosendahl
-
Publication number: 20100048872Abstract: The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.Type: ApplicationFiled: October 22, 2009Publication date: February 25, 2010Applicant: BOLDER BIOTECHNOLOGY, INC.Inventors: George N. Cox, III, Daniel H. Doherty, Mary S. Rosendahl
-
Publication number: 20100029563Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: ApplicationFiled: July 14, 2009Publication date: February 4, 2010Applicant: BOLDER BIOTECHNOLOGY, INC.Inventors: George N. Cox, III, Daniel J. Doherty
-
Patent number: 7629314Abstract: The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.Type: GrantFiled: May 27, 2004Date of Patent: December 8, 2009Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox, III
-
Publication number: 20090281281Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.Type: ApplicationFiled: February 24, 2009Publication date: November 12, 2009Applicant: Bolder Biotechnology, Inc.Inventor: George N. Cox III
-
Publication number: 20090269804Abstract: The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins.Type: ApplicationFiled: December 11, 2007Publication date: October 29, 2009Applicant: Bolder Biotechnology Inc.Inventors: Mary S. Rosendahl, George N. Cox, Daniel H. Doherty
-
Publication number: 20090249503Abstract: Disclosed are detoxifying enzyme conjugates, including conjugates of variants of such detoxifying enzymes. The detoxifying enzymes are preferably chlolinesterases, and more preferably, butyrylcholinesterase. Also disclosed are methods of making and using such conjugates.Type: ApplicationFiled: December 6, 2005Publication date: October 1, 2009Applicant: BOLDER BIOTECHNOLOGY, INC.Inventor: Mary S. Rosendahl